Pharmaceutical Company Reports Promising Alzheimer's Trial Data
A monoclonal antibody treatment has shown a statistically significant slowing of cognitive decline in an early-stage Alzheimer's population.
A major pharmaceutical company has reported positive Phase III trial results for an antibody-based treatment targeting early-stage Alzheimer's disease, showing a statistically significant 35% slowing in the rate of cognitive decline compared with placebo over an 18-month trial period.
The drug works by clearing amyloid plaques from the brain, building on a mechanism that has previously shown mixed results but in this trial was combined with a patient selection approach using PET imaging to identify those most likely to benefit.
Regulatory submissions are planned in multiple major markets by year end, with approval decisions potentially following within twelve to eighteen months if reviews proceed on standard timelines.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (3)